Hidradénite Suppurée : Qu’est-ce qui se Pointe à L’Horizon?
Résumé
L’hidradénite suppurée (HS) est une maladie inflammaidtoire chronique de la peau pour laquelle on ne dispose que d’un nombre limité d’options thérapeutiques efficaces. Depuis quelques années, des progrès ont été réalisés dans la compréhension de la physiopathologie de l’HS, ce qui a permis de mettre au point de nouvelles options thérapeutiques.
L’algorithme actuel de prise en charge de l’HS est décrit dans les lignes directrices nord-américaines sur le traitement et propose une combinaison de modalités de traitement médical et chirurgical. Les lignes directrices ont pour objet d’aider les cliniciens à prendre les meilleures décisions thérapeutiques, tout en adoptant une approche individualisée pour chaque cas. Les recommandations de prise en charge médicale comprennent des traitements topiques et intralésionnels, des antibiotiques systémiques, des agents hormonaux, des rétinoïdes, des immunosuppresseurs et des produits biologiques. Les traitements immunomodulateurs occupent une place importante dans la prise en charge de l’HS et seront au cœur du présent article.
Références
Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019; 81:91-101.
Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus: surgical approach. Dermatologic Surgery New York: Marcel Dekker. 1989;729-739.
Kimball AB. Jemec GB, Yang M et al. Assessing the validitiy, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171:1434-1442.
Kimball AB, Sobell JM, Zouboulis CC et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol. 2016;30:989-994.
Zouboulis CC, Bechara FG, Dickinson-Blok JL et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization- systematic review and recommendations from the HS ALLIANCE working group. JEADV. 2019;33:19-31.
Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Eng J Med. 2016;375:422-434.
ZoubulisCC, Okun MM, Prens EP et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):60-69.e2, available online https://doi.org/10.1016/j.jaad.2018.05.040.
Gulliver W, Alavi A, Papp, KA et al. Improvement of the quality of life of patients with moderate to severe hidradenitis suppurativa treated with adalimumab: The Solace study final analysis. Presented at the 9th conference of the European Hidradenitis Suppurativa Foundation, Athens, Greece. 2020 Feb 5-7.
Hafner A, Ghislain PD, Kovacs R, et al. Improvement in Hidradenitis Suppurativa and Quality of Life in Patients Treated with Adalimumab: Real-World Results from the HARMONY Study. Presented at the 9th Conference of the European Hidradenitis Suppurativa Foundation, 5-7 February 2020, Athens, Greece.
Grant A, Gozalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;61:205-217.
Paradela S, Rodriguez-Lojo R, Fernandez-Torres R. Long-term efficacy of infliximab in hidradenitis suppurativa. J Dermatolog Treat. 2012; 23:278-283.
Moriarty B, Jiyad Z, Creamer D. Four-weekly infliximab in the treatment of severe hidradenitis suppurativa. Br J Dermatol. 2014;170:986-987.
Adams D, Yankura JA, Fogelberg AC et al. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146(5):501-504.
Tampouratzi E, Kanni T, Katsantonis J. Case report: treating a combination of hidradenitis suppurativa and psoriasis with different therapeutic approaches. 2019. F1000research.com.
Abad SJ, Palacios MM, Pastor MV. A case report of hidradenitis suppurativa treated with certolizumab. J Am Acad Dermatol. 2019. available online https://doi.org/10.1016/j.jaad.2019.10.098.
Porter ML, Golbari NM, Lockwood SJ et al. Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa. Semin Cutan Med Surg. 2018;37(3):182-189.
Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 2016;152:52-59.
Leslie KS, Tripathi SV, Nguyen TV, et al. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol. 2014;70:243-251.
Blok JL, Li K, Brodmerkel C. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 2016;174:839-846.
Sharon VR, Shirakawa Garcia M, Bagheri S. Management of recalcitrant hidradenitis suppurativa with Ustekinumab. Acta Dermatol Venereol. 2012;92:320-335.
Gulliver W.P, Jemec GBE, Baker KA. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol. 2011. available online https://doi.org/10.1111/j.1468-3083.2011.04123.x.
Montero-Vilchez T, Pozo-Román T, Sánchez-Velicia L, et al. Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review, J Dermatol Treat. 2020. Available online https://doi.org/10.1080/09546634.2020.1755008.
Matusiak L, Szczech J, Bieniek A et al. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with IL-17 agents. J Am Acad Dermatol. 2017;76:670-675.
Kelly G, Hughes R, McGarry T. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol. 2015;173:1431-1439.
Casseres R, Prissiak L, Zanccanaro P. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open label trial. J Am Acad Dermatol. 2020;82:1524-1526.
Reguiai Z, Fougerousse AC, Maccari F. Effectiveness of secukinumab in hidradenitis suppurativa : an open label study (20 cases). J Eur Acad Dermatol. 2020. available online https://doi.org/10.1111/jdv.16605.
Thoriacius L, Theut Riis P, Jemec GBE. Severe hidradenitis suppurativa responding to treatment with secukinumab. J Eur Acad Dermatol. 2017. Available online https://doi.org/10.1111/bjd.15769.
Schuch A, Fischer T, Boehner A et al. Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab. Acta Dermatol Venereol. 2017;98:151-152.
Jorgensen AHR, Yao Y, Thomsen SF. Therapeutic response to Secukinumab in a 36-year-old woman with hidradenitis suppurativa. Case reports Dermatol Med (hindawi.com). 2018. https://doi.org/10.1155/2018/8685136.
Giuseppe P, Nicola P, Valentina C et al. A case report of Moderate Hidradenitis Suppurativa and psoriasis treated with Secukinumab. Ann Dermatol. 2018;30:462-464.
Megna M, Ruggiero A, Di Guida A et al. Ixekizumab: An efficacious treatment for both psoriasis and hidradenitis suppurativa. Dermatol Ther. 2020. Available online https://doi.org/10.1111/dth.13756.
Kirsten N, Augustin M. Two cases of hidradenitis suppurativa successfully treated with ixekizumab. Poster 0066, 28th EADV Congress, Madrid, Spain.
Frew JW, Navrazhina K, Grand D et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open label study. J Am Acad Dermatol. 2020. In press, https://doi.org/10.1016/j.jaad.2020.05.007.
Jemec G, Sayed C, Schmieder G et al. Efficacy and safety of bimekizumab, a dual interleukin (IL)-17A and ILF inhibitor, for the treatment of moderate to severe hidradenitis suppurativa (HS): a 12-week, randomised, double-blind, placebo controlled, Phase 2 study. Exp Dermatol. 2020;abstract 79.
Schlapbach C, Hanni T, Yawalkar N et al. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65:790-798.
Casseres R, Kahn J, Her MJ, et al. Guselkumab in the treatment of hidradenitis suppurativa: a retrospective chart review. J Am Acad Dermatol. 2019;81:265-267.
Berman HS, Villa NM, Shi VY et al. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis and Crohn’s disease. J Dermatol Treat. 2019. Available online, https://doi.org/10.1080/09546634.2019.1654067.
Kearney N. Byrne N, Kirby B, et al. Successful use of guselkumab in the treatment od severe hidradenitis suppurativa. Clin Exp Dermatol. 2020. Available online https://doi.org/10.1111/ced.14199.
Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019. Available online https://doi.org/10.3389/fimmu.2019.02847.
Gottlieb A, Natsis N, Kerdel F et al. A phase II open-label study of Bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain. J Invest Dermatol. 2020. Available online https://doi.org/10.1016/j.jid.2019.10.024.
